HPV Vaccine Triggers Regression of Precancers.
According to a phase IIb clinical trial, an investigational DNA vaccine that targets the human papillomavirus caused precancerous cervical lesions to regress or disappear. The vaccine stimulated production of CD8+ T cells that make perforin, a protein that helps kill infected cervical cells, and eliminated the virus in 81% of women whose lesions regressed.
D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D011230:Precancerous Conditions; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000473:pathology* / Q000628:therapy*
D053918:Papillomavirus Vaccines